Angiogenesis in liver metastasis of colo-rectal carcinoma

Frontiers in Bioscience

Volumn 18, Issue 4, 2013, Pages 1435-1443

  Xu, Bo ^a   Shen, Fei ^a   Cao, Jie ^a   Jia, Lin ^a  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Angiogenesis; Colorectal cancer; Liver metastasis; Review

Indexed keywords

EID: 84880562320     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4190     Document Type: Article

References (89)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62, 10-29 (2012).
2. Greene FL: AJCC Cancer Staging Manual. 6th ed. Chicago, Illinois, Springer (2002).
3. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96, 1420-5 (2004). (Pubitemid 39429665)
4. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM: The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199, 502-8 (1984). (Pubitemid 14105105)
5. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J: Factors infl uencing the natural history of colorectal liver metastases. Lancet 343, 1405-10 (1994). (Pubitemid 24167517)
6. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141, 586-9 (1981). (Pubitemid 11099239)
7. Mancini R, Ettorre G, Vennarecci G, Sperduti I, Garufi C, Esposito A, et al: Personal experience on treatment of colorectal liver metastases, a multidisciplinary approach. J Exp Clin Cancer Res 22(4 Suppl), 213-7 (2003). (Pubitemid 38436460)
8. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G: A populationbased study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93, 465-74 (2006).
9. Penna C, Nordlinger B: Colorectal metastasis (liver and lung) Surg Clin N Am 82, 1075-1090 (2002). (Pubitemid 35463085)
10. Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, et al: Treatment of hepatic metastases from colorectal cancer, many doubts, some certainties. Cancer Treat Rev 32, 214-228 (2006).
11. Ercolani G, Cucchetti A, Cescon M, Ravaioli M, Grazi GL, Pinna AD: Predictive indices of morbidity and mortality after liver resection. Ann Surg 244, 635-637 author reply 637 (2006). (Pubitemid 44435786)
12. Folkman J, Klagsbrun M: Angiogenic factors. Science 235, 442-447 (1987). (Pubitemid 17009577)
13. Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
14. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl. 16), 15-18 (2002).
15. Oklu R, Walker TG, Wicky S, Hesketh R: Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol 21(12), 1791- 1805 (2010).
16. Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer, association with clinical outcomes and prognostic implications. BMC Cancer 9, 432 (2009).
17. Casimiro S, Luis I, Fernandes A, et al: Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis 29, 155-64.(2012).
18. Huang LE, Arany Z, Livingston DM, Bunn HR: Activarion of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271, 32253-9 (1996). (Pubitemid 26422262)
19. Sutter CH, Laughner E, Semenza GL: Hypoxiainducible factor lalpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 97, 4748-53 (2000). (Pubitemid 30238629)
20. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, et al: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77(6), 998-1002 (1998). (Pubitemid 28101792)
21. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4), 549-80 (2004). (Pubitemid 39658463)
22. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95(4), 1789-97 (1995).
23. Cheng J, Slavin RE, Gallagher JA, Zhu G, Biehl TR, Swanstrom LL, et al: Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases. J Hepatobiliary Pancreat Surg 11(3), 164-70 (2004). (Pubitemid 38996939)
24. Wittig BM, Kaulen H, Thees R, Schmitt C, Knolle P, Stock J, et al:. Elevated serum E-selectin in patients with liver metastases of colorectal cancer. Eur J Cancer 32A(7), 1215-8 (1996).
25. Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, et al: Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 85(4), 502-6 (1998). (Pubitemid 28175443)
26. Gervaz P, Scholl B, Mainguene C, Poitry S, Gillet M, Wexner S: Angiogenesis of liver metastases, role of sinusoidal endothelial cells. Dis Colon Rectum 43(7), 980-6 (2000). (Pubitemid 30464071)
27. Zvibel I, Wagner A, Pasmanik-Chor M, Varol C, Oron- Karni V, Santo EM, et al: Transcriptional profiling identifies genes induced by hepatocyte-derived extracellular matrix in metastatic human colorectal cancer cell lines. Clin Exp Metastasis 30(2), 189-200 (2013).
28. Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ: Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer 112(4), 554-9 (2004). (Pubitemid 39425934)
29. Lejmi E, Leconte L: Netrins and their receptors in normal and pathological angiogenesis. In "Adhesion and Guidance Receptors in Angiogenesis", Editor Julie Gavard, Transworld Research Network, India, chapter 6, 119-138 (2010).
30. Eveno C, Contreres JO, Hainaud P, Nemeth J, Dupuy E, Pocard M: Netrin-4 overexpression suppresses primary and metastatic colorectal tumor progression. Oncol Rep 29(1), 73-8 (2013).
31. Karube H, Masuda H, Hayashi S, Ishii Y, Nemoto N: Fatty liver suppressed the angiogenesis in liver metastatic lesions. Hepatogastroenterology 47(36), 1541-5 (2000).
32. Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, Hong SW, et al: Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res 64(19), 7092-8 (2004).
33. Liebig C, Agarwal N, Ayala GE, Verstovsek G, Tuszynski GP, Albo D: Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model. J Surg Res 142(2), 320-6 (2007). (Pubitemid 47418821)
34. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, et al: Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63(9), 2079-87 (2003). (Pubitemid 36538610)
35. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, et al: Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9), 3842-9 (2009).
36. Kuruppu D, Christophi C, Maeda H, O'Brien PE: Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol. J Surg Res 103(1), 47-54 (2002). (Pubitemid 34953391)
37. Ellis LM, Hicklin DJ: VEGF-targeted therapy, mechanisms of anti-tumour activity. Nat Rev Cancer 8, 579-591 (2008).
38. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor, a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20, 4368-4380 (2002). (Pubitemid 35266299)
39. Kerbel RS: Tumor angiogenesis. N Engl J Med 358, 2039-2049 (2008). (Pubitemid 351656458)
40. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36(2), 127-37 (1995).
41. Harmey JH, Bouchier-Hayes D: Vascular endothelial growth factor (VEGF), a survival factor for tumour cells, implications for anti-angiogenic therapy. Bioessays 24(3), 280-3 (2002). (Pubitemid 34248694)
42. Lee JC, Chow NH, Wang ST, Huang SM: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36(6), 748-53 (2000).
43. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98(6), 1904-13 (2001).
44. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61(3), 1207-13 (2001). (Pubitemid 32174444)
45. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, et al: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59(21), 5412-6 (1999). (Pubitemid 29526446)
46. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, et al: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK), translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 57(6), 761-71 (2006).
47. Takahashi Y, Mai M: Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF. J Exp Clin Cancer Res 24(2), 237-43 (2005). (Pubitemid 41039608)
48. Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, et al: Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 58(15), 3209-14 (1998). (Pubitemid 28371053)
49. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, et al: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9(4), 1323-32 (2003). (Pubitemid 36418382)
50. http,//www.gene.com/gene/products/information/pdf/avastin-prescribing. pdf.
51. Ferrara N: Vascular endothelial growth factor, basic science and clinical progress. Endocr Rev 25, 581-611 (2004).
52. Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, et al: A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer 10, 545 (2010).
53. De Benedetti A, Harris AL: eIF-4E expression in tumors, its possible role in progression of malignancies. Int J Biochem Cell Biol 31, 59-72 (1999). (Pubitemid 29094790)
54. Raught B, Gingras AC: eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 31, 43-57 (1999). (Pubitemid 29094789)
55. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM: Integrin (α6β4) regulation of eIF-4E activity and VEGF translation, a survival mechanism for carcinoma cells. J Cell Biol 158, 165-74 (2002).
56. Murata K, Moriyama M: Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis. Cancer Res 67(7), 3263-8 (2007). (Pubitemid 46724864)
57. Murakami K, Sakukawa R, Sano M, Hashimoto A, Shibata J, Yamada Y, et al: Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101. Clin Cancer Res 5(9), 2304-10 (1999). (Pubitemid 29437306)
58. Minagawa N, Nakayama Y, Inoue Y, Onitsuka K, Katsuki T, Tsurudome Y, et al: 4-(3, 5- Bis(trimethylsilyl)benzamido) benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol Res 14(9), 407- 14 (2004). (Pubitemid 39304308)
59. Deshayes F, Nahmias C: Angiotensin receptors, a new role in cancer? Trends Endocrinol Metab 16(7), 293-299 (2005). (Pubitemid 41206635)
60. Ager EI, Neo J, Christophi C: The renin-angiotensin system and malignancy. Carcinogenesis 29(9), 1675-1684 (2008).
61. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C: Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 22(4), 577-584 (2007). (Pubitemid 46434989)
62. Ager EI, Chong WW, Wen SW, Christophi C: Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell Int 10, 19 (2010).
63. Ager EI, Wen SW, Chan J, Chong WW, Neo JH, Christophi C: Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation. BMC Cancer 11, 274 (2011).
64. Sheehan KM, Steele C, Sheahan K, O'Grady A, Leader MB, Murray FE, et al: Association between Cyclooxigenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer. Histopathology 46, 287-95 (2005). (Pubitemid 40343175)
65. Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GJ, Lodge JP: Cyclooxigenase-2 expression in colorectal cancer liver metastases. Clin Exp Metast 18, 21-7 (2000). (Pubitemid 32096045)
66. Brown J, DuBois RN: COX-2 a molecular Target for colorectal cancer prevention. J Clin Oncol 23(12), 2840-55 (2005). (Pubitemid 46179475)
67. Garcea G, Sharma RA, Dennison A, Steward WP, Gesher A, Berry DP: Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Eur J Cancer 39, 1041-52 (2003). (Pubitemid 36555860)
68. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K: Cyclooxigenase-2 expression in endometrial cancer, correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 33(2), 213-9 (2002). (Pubitemid 34298737)
69. Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GJ, Lodge JP: Cyclooxigenase-2 expression in colorectal cancer liver metastases. Clin Exp Metast 18, 21-7 (2000). (Pubitemid 32096045)
70. Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, et al: Correlations between cyclooxygenase- 2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 37(9), 679-85 (2007). (Pubitemid 47617787)
71. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, et al: Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11(4), 1618-28 (2005). (Pubitemid 40315247)
72. Fenwick SW, Toogood GJ, Lodge JP, Hull MA: The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125(3), 716-29 (2003). (Pubitemid 37070690)
73. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 94(12), 6099-103 (1997). (Pubitemid 27270643)
74. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348(6301), 555-7 (1990). (Pubitemid 120015110)
75. Gervaz P, Scholl B, Padrun V, Gillet M: Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470. Liver 20(2), 108-13 (2000). (Pubitemid 30219136)
76. Sano J, Sugiyama Y, Kunieda K, Sano B, Saji S: Therapeutic effect of TNP-470 on spontaneous liver metastasis of colon tumors in the rabbit. Surg Today 30(12), 1100-6 (2000). (Pubitemid 32095983)
77. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, et al: Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 61(2), 268-71 (1995).
78. Takatsuka S, Yamada N, Sawada T, Ogawa Y, Maeda K, Ohira M, et al: Contribution of angiogenesis to the progression of colon cancer, possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int J Oncol 17(2), 253-8 (2000).
79. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, et al: Histologic features and clinical significance of venous invasion in colorectal carcinoma with hepatic metastasis. Cancer 78(11), 2313-7 (1996). (Pubitemid 26392829)
80. Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T: Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum 39(10), 1073-80 (1996). (Pubitemid 26330513)
81. Miyagawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T: Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 35(11), 1392-6 (2004). (Pubitemid 39601580)
82. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, et al: Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 99(10), 1729-34 (2008).
83. Eda I, Soga H, Ueoka M, Okada A, Yamashita K, Shimizu N: The suppression of postoperative liver metastasis caused by the continuous intraportal infusion of angiogenesis inhibitor FR-118487 in a rabbit colon cancer model. Surg Today 28(3), 273-8 (1998). (Pubitemid 28165917)
84. Eda I, Soga H, Ueoka M, Yamashita K, Kawasaki S, Doihara H, et al: Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487. Gan To Kagaku Ryoho 22(11), 1480-2 (1995).
85. Folkman J: Antiangiogenesis in cancer therapy- endostatin and its mechanisms of action. Exp Cell Res 312 (5), 594-607 (2006). (Pubitemid 43290336)
86. Feldman AL, Alexander HR Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, et al: A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 8(9), 741-5 (2001). (Pubitemid 32952490)
87. Zhou ZW, Wan DS, Wang GQ, Ren JQ, Lu ZH, Lin SX, et al: Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer. Ai Zheng 25(7), 818-22 (2006).
88. Zhou ZW, Wan DS, Wang GQ, Ren JQ, Lu ZH, Tang SX, et al: Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi 9(2), 161-4 (2006).
89. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, et al: Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 104(4), 496-503 (2003). (Pubitemid 36323922)